The Coalition for Epidemic Preparedness Innovations and COVAX partners are setting up a ‘marketplace’ that will match sellers and buyers of vital production supplies, in turn expediting worldwide manufacturing of Covid-19 vaccine doses and access to those vaccines. Initially, the marketplace will have about 10-15 participants, including COVAX vaccine producers and suppliers of the necessary materials. The plan is to expand the initiative to make other vaccines and therapies impacted by supply shortages in the future.

Ocugen has started a rolling submission to Health Canada, seeking authorisation for its Covid-19 vaccine, COVAXIN, which is being developed in partnership with Bharat Biotech International. The submission comes after Bharat Biotech reported data from Phase III trials, where the vaccine showed safety and efficacy in approximately 25,800 adults. Ocugen affiliate Vaccigen initiated the rolling submission, which will be reviewed by the Canadian regulatory agency to decide on approval.

ExeVir has entered a partnership to leverage the fill and finish capabilities of Mithra Pharmaceuticals for the production of its anti-SARS-CoV-2 antibody, XVR011, being developed to both treat and prevent Covid-19. Under the deal, Mithra will handle upscaling and production services to fill the drug substance for supporting clinical and commercial supply.